234,180 Shares in Krystal Biotech, Inc. $KRYS Acquired by Nuveen LLC

Key Points

• Nuveen LLC acquired 234,180 shares of Krystal Biotech, Inc. valued at approximately $42 million, representing 0.81% ownership of the company at the end of the most recent quarter.
• The stock has significant institutional interest, with 86.29% of shares held by institutional investors and hedge funds, indicating strong market confidence.
• Krystal Biotech reported an EPS of $1.29 in its last quarterly earnings, exceeding the consensus estimate, along with a 40.85% net margin and revenue of $96.04 million.

Nuveen LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 234,180 shares of the company's stock, valued at approximately $42,223,000. Nuveen LLC owned 0.81% of Krystal Biotech at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of KRYS. Avoro Capital Advisors LLC raised its position in Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after purchasing an additional 6,600 shares in the last quarter. Hood River Capital Management LLC lifted its position in Krystal Biotech by 2.1% in the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after buying an additional 10,622 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after buying an additional 71,200 shares during the last quarter. Soleus Capital Management L.P. boosted its stake in Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after buying an additional 141,400 shares in the last quarter. Finally, Northern Trust Corp grew its position in Krystal Biotech by 9.9% during the fourth quarter. Northern Trust Corp now owns 262,263 shares of the company's stock valued at $41,086,000 after acquiring an additional 23,572 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the transaction, the insider owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 49,800 shares of company stock valued at $7,487,943 in the last ninety days. 13.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have weighed in on KRYS. Chardan Capital reissued a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Tuesday, August 5th. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Friday, July 25th. Bank of America reduced their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Citigroup reaffirmed a "neutral" rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $210.75.

Krystal Biotech Price Performance

Krystal Biotech stock traded up $1.67 during mid-day trading on Wednesday, reaching $145.63. 109,526 shares of the company traded hands, compared to its average volume of 331,590. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84. The firm has a market capitalization of $4.21 billion, a price-to-earnings ratio of 29.60 and a beta of 0.70. The firm's 50 day moving average price is $143.72 and its 200 day moving average price is $154.83.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The business had revenue of $96.04 million for the quarter, compared to analysts' expectations of $95.42 million. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).